Sytheon has been issued its latest patent for Synoxyl AZ (INCI: Acetyl Zingerone).
U.S. Patent 10,828,241 discloses compositions and methods to even skin tone and lighten normal and/or hyperpigmented skin, comprised of: one or more aryl alkanones; optionally, at least one other skin lightening agent; and a dermatologically acceptable carrier.
The company has discovered that Synoxyl AZ functions not only as a non-sacrificial antioxidant, anti-inflammatory and anti-aging ingredient, but also helps to manage skin pigmentation by modulating three distinct non-tyrosinase pathways. Furthermore, according to Sytheon, acetyl zingerone can be combined with Synovea HR (INCI: Hexylresorcinol) to boost its efficacy in managing and controlling skin pigmentation, thanks to non-overlapping mechanistic pathways.
This patent could lead to the development of a more efficacious molecule to treat or prevent the effects of intrinsic and extrinsic skin aging, as well as to manage areas of hyperpigmentation on the skin.
For more information, contact Sytheon.